Drugs in Dev. Gastroenterology
Phase I/ Phase II
Switzerland 
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KAN-101 is an investigational treatment for Celiac Disease (CeD). It encompasses a well-described gluten antigen that is implicated in driving the onset of Celiac Disease.
Product Name : KAN-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 05, 2023
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KAN-101 is an investigational treatment for Celiac Disease (CeD). It encompasses a well-described gluten antigen that is implicated in driving the onset of Celiac Disease.
Product Name : KAN-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2022
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KAN-101 is an investigational therapy being evaluated as a treatment for individuals with celiac disease, a serious autoimmune disease triggered by ingestion of gluten, for which there are no approved therapeutic treatments available.
Product Name : KAN-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2022
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : $35.0 million
Deal Type : Financing
Anokion Announces $35 Million Equity Investment from Pfizer
Details : Anokion and Pfizer have entered into an agreement to leverage Pfizer’s development expertise and capabilities in support of the continued clinical development of KAN-101, Anokion’s lead candidate for the treatment of individuals with celiac disease.
Product Name : KAN-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 18, 2022
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : $35.0 million
Deal Type : Financing
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : $35.0 million
Deal Type : Financing
Anokion Announces $35 Million Equity Investment from Pfizer
Details : Anokion and Pfizer have entered into an agreement to leverage Pfizer’s development expertise and capabilities in support of the continued clinical development of KAN-101, Anokion’s lead candidate for the treatment of individuals with celiac disease.
Product Name : KAN-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 18, 2022
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : $35.0 million
Deal Type : Financing
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : SVB Securities
Deal Size : $30.0 million
Deal Type : Public Offering
VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares
Details : VectivBio intends to use the net proceeds, together with its existing cash and cash equivalents, available for sale and short-term deposits: to fund clinical development and pre-commercialization activities for its lead product candidate FE203799 (Apragl...
Product Name : FE203799
Product Type : Peptide
Upfront Cash : Undisclosed
June 15, 2022
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : SVB Securities
Deal Size : $30.0 million
Deal Type : Public Offering
Reset All
